159 related articles for article (PubMed ID: 30546143)
1. A National Quality Assurance program for breast immunohistochemistry: an Italian perspective.
Guadagno E; De Rosa G; Nappi O
Pathologica; 2018 Sep; 110(2):83-91. PubMed ID: 30546143
[TBL] [Abstract][Full Text] [Related]
2. Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.
Ekholm M; Grabau D; Bendahl PO; Bergh J; Elmberger G; Olsson H; Russo L; Viale G; Fernö M
Acta Oncol; 2015 Jul; 54(7):1040-8. PubMed ID: 25959664
[TBL] [Abstract][Full Text] [Related]
3. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.
Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M
J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860
[TBL] [Abstract][Full Text] [Related]
4. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
5. Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study.
Kraus JA; Dabbs DJ; Beriwal S; Bhargava R
Mod Pathol; 2012 Jun; 25(6):869-76. PubMed ID: 22301704
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
Xian Z; Quinones AK; Tozbikian G; Zynger DL
Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
[TBL] [Abstract][Full Text] [Related]
7. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program.
Francis GD; Dimech M; Giles L; Hopkins A
J Clin Pathol; 2007 Nov; 60(11):1277-83. PubMed ID: 17259294
[TBL] [Abstract][Full Text] [Related]
8. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
Calhoun BC; Collins LC
Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
[TBL] [Abstract][Full Text] [Related]
9. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories.
Regitnig P; Reiner A; Dinges HP; Höfler G; Müller-Holzner E; Lax SF; Obrist P; Rudas M; Quehenberger F
Virchows Arch; 2002 Oct; 441(4):328-34. PubMed ID: 12404057
[TBL] [Abstract][Full Text] [Related]
10. [Determination of tumor biological parameters in breast cancer: round robin testing for quality assurance].
Liessem S; Winkens W; Jonigk D; Wasielewski RV; Fisseler-Eckhoff A; Rüschoff J; Kreipe HH
Pathologe; 2014 Feb; 35(1):61-71. PubMed ID: 24496992
[TBL] [Abstract][Full Text] [Related]
11. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study.
Nishimura R; Murata Y; Mori K; Yamashiro K; Kuraoka K; Ichihara S; Taguchi K; Suzuki H; Ito M; Yamashita N
Acta Cytol; 2018; 62(4):288-294. PubMed ID: 29763896
[TBL] [Abstract][Full Text] [Related]
13. Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution.
Oluwasola AO; Malaka D; Khramtsov AI; Ikpatt OF; Odetunde A; Adeyanju OO; Sveen WE; Falusi AG; Huo D; Olopade OI
Ann Diagn Pathol; 2013 Dec; 17(6):526-30. PubMed ID: 24095629
[TBL] [Abstract][Full Text] [Related]
14. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
[TBL] [Abstract][Full Text] [Related]
15. [Receptor detection in breast cancer. A decade of quality assurance trials in German-speaking pathology].
Kreipe HH
Pathologe; 2011 Sep; 32(5):357-9. PubMed ID: 21847514
[No Abstract] [Full Text] [Related]
16. External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China.
Pu T; Shui R; Shi J; Liang Z; Yang W; Bu H; Li Q; Zhang Z;
BMC Cancer; 2019 Oct; 19(1):978. PubMed ID: 31640622
[TBL] [Abstract][Full Text] [Related]
17. [Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP. National Federation of Centres to Combat Cancer/French Association for Quality Assurance in Pathology].
Balaton AL; Coindre JM; Collin F; Ettore F; Fiche M; Jacquemier J; Le Doussal V; Mandard AM; Mathieu MC; Migeon C; Simony-Lafontaine J; Treilleux I; Verriele V; Vilain MO; Zafrani B
Ann Pathol; 1996; 16(2):144-8. PubMed ID: 8767687
[TBL] [Abstract][Full Text] [Related]
18. Proficiency testing of immunohistochemical biomarker assays in breast cancer.
Wasielewski Rv; Hasselmann S; Rüschoff J; Fisseler-Eckhoff A; Kreipe H
Virchows Arch; 2008 Dec; 453(6):537-43. PubMed ID: 18958494
[TBL] [Abstract][Full Text] [Related]
19. Updated UK Recommendations for HER2 assessment in breast cancer.
Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
[TBL] [Abstract][Full Text] [Related]
20. Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program.
Hung T; Wolber R; Garratt J; Kalloger S; Gilks CB
Pathology; 2010 Dec; 42(7):637-42. PubMed ID: 21080872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
